Semaglutide helps walking too

The STRIDE trial — a phase 3b, randomized, double‑blind study sponsored by Novo Nordisk and led by vascular researchers including Marc Bonaca and Subodh Verma — enrolled 792 adults with type 2 diabetes and symptomatic peripheral artery disease across 112 centers and reported its primary results at the American College of Cardiology meeting and in The Lancet (Mar 29, 2025). (thelancet.com)00509-4/fulltext) (acc.org) At 52 weeks the trial found clinically measurable gains: once‑weekly semaglutide 1.0 mg increased maximum walking distance versus placebo with an estimated treatment ratio of 1.13 (13% improvement) and a median treatment difference of 26.4 meters on a constant‑load treadmill set to a 12% incline, and also improved pain‑free walking distance and vascular quality‑of‑life scores. (prnewswire.com) (tctmd.com) Peripheral artery disease, or PAD, is the narrowing of leg arteries that reduces blood flow and causes claudication — muscle pain or cramping when walking — and STRIDE specifically enrolled people with early symptomatic PAD and measured walking capacity with a standardized treadmill test to capture functional improvement rather than only imaging or lab changes. (acc.org) (clinicaltrials.gov) Semaglutide is part of the glucagon‑like peptide‑1 receptor agonist (GLP‑1 RA) class, drugs originally developed to lower blood sugar and body weight; those drugs also have documented anti‑inflammatory and endothelial (blood vessel lining) effects — including reductions in vascular inflammation, oxidative stress, and improvements in microvascular blood flow — mechanisms that investigators hypothesize could explain benefits in leg blood flow and walking. (nature.com) (academic.oup.com) The trial’s statistical readouts: the primary endpoint used the ratio‑to‑baseline metric for maximum walking distance with mixed‑model repeated measures, yielding ETR 1.13 (95% CI 1.06–1.21; p=0.0004) and a median treatment difference of 26.4 m (95% CI 11.8–40.9) at week 52; key secondary outcomes included pain‑free walking (ETR 1.11; 95% CI 1.03–1.20; p=0.0046) and a VascuQoL‑6 quality‑of‑life improvement (difference 1.00; 95% CI 0.48–1.52; p=0.011), and overall safety was concordant with prior semaglutide data. (prnewswire.com) (diabetesjournals.org) A STRIDE subanalysis presented at the American Diabetes Association meeting reported semaglutide cut a pre‑specified composite of disease‑progression events (initiation of rescue therapy, all‑cause death, or major adverse limb events) by about 54%, and the walking and quality‑of‑life benefits were consistent across subgroups stratified by BMI, HbA1c, diabetes duration, and background diabetes medications. (diabetes.org) (adameetingnews.org)